Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

LegoChem, Longthera and Medicilon Form Collaboration to Co-develop New Antibiotic LCB01-0699

2013-11-29
|
Page View:

Co-develop New Antibiotic LCB01-0699

SHANGHAI, November 27, 2013 –LegoChem and Longthera today announced that they have entered into a collaboration agreement to co-develop LegoChem’s LCB01-0699, a novel antibiotic small molecule against linezolid resistant strains.

Under the terms of the agreement, LegoChem and Longthera Pharmaceutical will continue the development of LCB01-0699, with Longthera bearing part of the ongoing development cost. Longthera will receive part of commercial rights in China while LegoChem retains commercial rights outside of China. Medicilon will provide IND enabling studies for LCB01-0699, including the development and manufacturing of the drug candidate and pre-clinical development for both US FDA and CFDA IND filing.

“We are very enthusiastic about this partnership with Longthera and Medicilon, which allows us to team up with China’s leading pharmaceutical and CRO companies to efficiently develop LCB01-0699, a novel antibiotic small molecule against linezolid resistant strains,” said Dr. Yong Zu Kim, Chief Executive Officer of LegoChem. “This collaboration allows LegoChem to further extend our pipeline of new drug and gain access to the China market through our partnership with Longthera and Medicilon.”

Dr. Peng Cheng, CEO of Longthera Pharmaceuticals, commented, “We are indeed honored to partner with LegoChem in antibiotic drugs. We will work with Medicilon on its integrated service platform to accelerate the preclinical development of LCB01-0699 in China. The partnership will also help Longthera establish long-term and mutually beneficial relationships with leading global companies and advance our position in the biopharmaceutical industry.”

“Our collaboration with LegoChem and Longthera on LCB01-0699 is another example of how Medicilon’s IND enabling studies platform enables our partners to develop innovative products efficiently and cost-effectively to benefit the world’s patients,” said Dr. Chun-Lin Chen, CEO of Medicilon. “We are very pleased to offer our partners integrated services with IND enabling studies at global standards ranging from CMC development to all pre-clinical studies including pharmacokinetics, pharmacodynamics and GLP toxicological evaluation for both US FDA and CFDA IND filing.

Return
Relevant newsRelevant news